Alva, United Kingdom

Time filter

Source Type

News Article | November 23, 2016

According to Stratistics MRC, the Global Allergy Diagnostics Market is accounted for $2.70 billion in 2015 and is expected to reach $6.29 billion by 2022 growing at a CAGR of 12.8% during the forecast period. Factors such as rising healthcare expenses, growing environmental pollution, increasing geriatric population and huge financial burden of allergic diseases are fueling the market growth. However, stringent regulations and huge capital investments are hampering the market. Access the complete report at: The assay kits segment commanded the largest share of the global market and is also anticipated to grow at the fastest CAGR due to the growing count of allergic diseases. North America dominated the market owing to the increasing aging population and rising pollution due to urbanization in the region. However, the Asia Pacific is expected to grow at a faster pace due to presence of largely untapped market. Some of the key players in allergy diagnostics market include Siemens AG, Danaher Corporation, Omega Diagnostics Group PLC, HYCOR Biomedical, HOB Biotech Group Co., Ltd, Hitachi Chemical Diagnostics, Inc., Stallergenes Greer, BioMérieux, Thermo Fisher Scientific, Inc., Lincoln Diagnostics, Inc., Allercheck Inc., Bio-Diagnostics Ltd., SmartPractice Denmark ApS, ERBA Mannheim Group, Terumo Medical Corporation and Diagenics Ltd. Allergens Covered: • Seasonal Allergens • Inhaled Allergens o Dust Allergy • Drug Allergens • Anaphylaxis/Contact Allergens o Plant Origin o Insect Sting Allergy • Food Allergens • Other Allergens Products Covered: • Consumables  • Assay Kits  • Instruments  o Luminometers o Immunoassay Analyzers o Elisa Analyzers o Other Instruments   Diagnostic Test Types Covered: • In Vitro Tests o Blood Test • In Vivo Tests o Skin Test o Patch Test • Elimination Diet • Other Diagnostic Test Types End Users Covered: • Hospitals o Allergists / Immunologists o Physicians • Academic Research Institutes • Diagnostic Laboratories o Pathology Laboratories • Other End Users Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK  o Spain o Rest of Europe       • Asia Pacific o Japan        o China        o India        o Australia        o New Zealand       o Rest of Asia Pacific • Rest of the World o Middle East o Brazil       o Argentina        o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements

News Article | November 24, 2016

Recently a test has been created which can determine patient history for viral infections through one drop of blood where the antibodies remain active even after the infection is moved out. The test compares viral infection in large population with great accuracy and is proved to be an alternative for viral testing methods which detects specific types of viruses. According to Centers for Disease Control and Prevention, there were 59 outbreaks of viral hepatitis during 2008 to 2015 from which hepatitis B virus and hepatitis C virus infections accounted for greatest burden of disease. As viral hepatitis infections are asymptomatic and were not completely identified or reported. A report by WHO (World Health Organization) revealed that, there are more 357 million new infections detected annually and along with 500 million people with genital infections. Due to growing epidemiology of viral infections the blood virus testing market is estimated to drive growth over the years. Diagnostic virology has evolved from the traditional viral diagnostics and has achieved diagnosis by scanning a single drop of blood. Globally, there is rapid increase in number viral infections which are difficult to diagnose due to the nature of viruses which has surged the demand for viral testing. Blood virus testing has been proved to be successful in diagnosis of such viruses and thus blood virus testing market is estimated to represent colossal growth during the forecast period (2016-2024). Various research organizations such as Howard Hughes Medical Institute are working to develop one-stop-shop testing for viruses and have been successful recently. Improving research and medical facilities powered by technology is expected to develop new market opportunities for blood virus testing over the forecast years. On the basis of region presence, Blood virus testing market is segmented into five key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America market is estimated to lead the global market for blood virus testing due to high prevalence rate of viral infectious diseases such as hepatitis, followed by Europe due to the rising cases of severe acute respiratory syndrome (SARS) and Zika virus. According to the epidemiology of viral infections such as Ebola and Zika virus worldwide, the need for blood virus testing is raised. However, factors such as lack of accessibility to healthcare facilities and limited awareness about viral infections are likely to hamper the market especially in the developing economies. Request TOC (desk of content material), Figures and Tables of the report: Some of the key market players in the manufacturing of the treatment products (drugs) for Blood Virus Testing includes F. Hoffmann-La Roche Ltd, bioMérieux SA, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Omega Diagnostics Group PLC, Randox Laboratories Ltd.,  OraSure Technologies, Inc.

A number of scientific publications have been published recently dealing with the use of single recombinant allergens for the detection of specific IgE antibodies in vitro. Primarily microarray-based systems have been used in this context. A prerequisite for a routine use of recombinant allergens is a comparable IgE-binding capacity as natural single allergens. Our investigation shows that natural and recombinant single allergens are indeed comparable regarding to their IgE antibody reactivities. Natural and recombinant allergens were pure since only one protein band was detectable by SDS-PAGE. Measurements performed by EAST-Inhibition revealed, that recombinant allergens show nearly similar allergenic potencies compared with natural allergens. Irrespectively of whether recombinant or natural allergens were used identical EAST-classes (class 0/≥1) were measured with sera obtained from different sensitized patients in most experiments. In some cases a little bit higher classes were measured with the native allergen discs. In summary the purity of both recombinant and native extracts were found to be comparable and may be employed for IgE measurements. © 2011 Dustri-Verlag Dr. Karl Feistle.

Our aim was to investigate the usefulness of the Component-Resolved Diagnosis system (CRD) in comparison to the classical specific IgE-system. The aim was not to compare the two systems, but rather the relative merrits of single allergens versus whole allergen extracts. Investigations showed, that the use of single allergens for specific IgE measurements gives neither better, nor diagnostically more relevant results than allergen discs produced with total native allergen extracts. For example, EAST-class measurements with a Dermatophagoides pteronyssinus allergen disc and the allergen discs nDer p1 and nDer p2. Our investigations showed also, that specific IgE measurement of birch pollen sensitized patients can be done equally well with Bet v1 discs, although no additional information could be obtained with respect to the class-measurement. IgE-measurement for Alternaria tenuis sensitized patients can be done by using an Alt a1-allergen disc. The measurement of English plantain sensitized patients can not be substituted by measurement with Pla l1-allergen discs, as the use of total allergen discs identified more patients with a positive reaction. For the measurement of timothy pollen-sensitized patients a cocktail allergen disc must be used, produced on the basis of the respective single allergens to achieve the same result as obtained by measurement with the total allergen disc. One advantage of single allergens - especially recombinant allergens - is that they can be better standardized than total allergen extracts. As long as there are no preparations of single allergens available on the market for specific immunotherapy - here the CRD will be very useful - measurements with single allergens are only of scientific interest, and generally speaking not relevant for use in a routine laboratory. © 2011 Dustri-Verlag Dr. Karl Feistle.

Comparative specific IgE measurements performed with total and single allergen disks showed that the use of single allergen disks, as compared to a total allergen disk, provided no advantage, since it resulted in comparable spec. IgE titers. This was demonstrated in measurements sera of house dust mite sensitized patients with the (native) Der p1- and nDer p2-allergen disks and by measurement of sera of timothy grass pollen sensitized patients, using nPhl p1- and nPhl p5- allergen disks. The EAST-classes of both the total and single allergen disks measured were comparable in most cases. The deployment of single allergen disks will be of particular importance, as soon as therapy extracts on the basis of recombinant single allergens will be available to treat the patient according to his/her sensibilisation pattern, but this is currently not the case. In contrast single and cocktail preparations for specific immunotherapy might be available in the future. © 2015 Dustri-Verlag Dr. Karl Feistle.

Solid phases with allergen mixes are very useful for the initial diagnosis in allergic sensitization. It is very important, that while measuring a positive signal with the mix allergen disc, at least one allergen of the mixture gives a positive response. In our investigations with inhalant allergens and food allergens we could demonstrate this. Furthermore we could show, that the mix allergen discs did not give rise to a false positive result.Aclass 0 obtained with the mix allergen disc was also measured with the single allergen discs. Using mix allergen discs the result is not only expressed as positive or negative but also in classes and U/ml. In this way it is possible to make a better comparison of the data. Solid phases with allergen mixes are suitable screening instruments for the detection of atopic individuals, the detection of specific sensitizations in case of imprecise histories and for the exclusion of sensitizations. © 2011 Dustri-Verlag Dr. Karl Feistle.

Fiebig P.,University of Leipzig | Fiebig P.,Omega Diagnostics | Shehata A.A.,University of Leipzig | Shehata A.A.,Sadat City University | Liebert U.G.,University of Leipzig
Virus Research | Year: 2015

H5-specific monoclonal antibodies may serve as valuable tools for rapid diagnosis of H5N1 avian influenza virus. Therefore, conserved H5-specific sequences of the haemagglutinin (HA) protein were expressed in Pichia pastoris and used for generation of monoclonal antibodies (mAbs). The two mAbs, FD6 and HE4, were strongly reactive against native HA protein and exhibited specificity for subtype H5. By epitope mapping linear epitopes of mAbs were identified that are highly conserved among influenza A virus of subtype H5. Additionally no sequence similarities to homologous regions on HA proteins of other influenza A virus subtypes (i.e. H1, H3, H7, H9) were detected by sequence alignment analysis. Both mAbs did not cross react with native or denatured HA proteins of other influenza A virus subtypes. Furthermore, using ELISA and immunofluorescence test mAb FD6 reacted only to the native H5 protein of recently circulating highly pathogenic H5N1 influenza viruses but not to low pathogenic H5N1 isolates. In conclusion, the use of the two mAbs in non-molecular tests like antigen-capture-ELISA appears promising for detecting influenza A H5N1 virus. © 2015 Elsevier B.V.

Omega Diagnostics | Date: 2011-07-11

Chemical reagents and diagnostic preparations for in vitro use for allergy testing for scientific or research use in scientific laboratories. Chemical reagents and diagnostic preparations for in vitro use for allergy testing for medical and veterinary use as an aid in clinical diagnosis; chemical reagents for in vitro use for allergy testing for medical and veterinary purposes; diagnostic preparations for in vitro use for allergy testing for medical purposes; diagnostic test kits for testing allergies consisting primarily of diagnostic reagents and preparations. Medical apparatus and equipment for medical or veterinary purposes, namely, diagnostic apparatus for the detection of allergies; diagnostic test kits for medical or veterinary purposes consisting primarily of diagnostic apparatus for the detection of allergies; diagnostic test kits for testing allergies consisting primarily of diagnostic apparatus for the detection of allergies.

Omega Diagnostics | Date: 2011-06-17

Diagnostic preparations, substances and reagents, all for medical or veterinary use. Medical apparatus and equipment; diagnostic test kits; diagnostic test kits for testing allergies.

Loading Omega Diagnostics collaborators
Loading Omega Diagnostics collaborators